Hoth Therapeutics announces FDA acceptance of IND application for HT-001

Hoth Therapeutics announced that the U.S. Food and Drug Administration, FDA, has accepted an Investigational New Drug, IND, application for the company’s HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor, EGFR, inhibitor therapy. "We are excited to begin our trial and bring hope to patients who are suffering. With no specific treatment currently approved for the treatment of skin toxicities associated with EGFRi therapies, this trial brings us one step closer to a new treatment option for underserved cancer patients," said Robb Knie, CEO of Hoth Therapeutics, Inc. "We look forward to advancing HT-001 into the clinical phase as we believe that this novel therapeutic will be a key treatment in the onco-dermatology space. We anticipate beginning our Phase 2a trial in Q1 of 2023."